Research graph
References from Determination of 5-Fluorouracil, 5,6-dihydro-5-Fluorouracil, Uracil and Dihydrouracil by UPLC-MS/MS in plasma and its application in hepatocellular carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
The prodrugs of 5-fluorouracil
10.2174/1568011023354146 · 2002 · External reference
Guideline for the diagnosis and treatment of primary hepatocellular carcinoma (2024 edition)
2024 · External reference
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1)
10.1200/jco.21.01963 · 2022 · External reference
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
10.1200/jco.21.00608 · 2022 · External reference
Research progress on cardiotoxicity of 5-fluorouracil and prevention with traditional Chinese medicine
2021 · External reference
Individualization of 5-Fluorouracil in the Treatment of Colorectal Cancer
2010 · External reference
Correlation between steady-state plasma concentration of 5-fluorouracil and individual pharmacological differences and toxicity in the FOLFOX6 regimen
2017 · External reference
Research progress on dose selection of 5-fluorouracil
2013 · External reference
Therapeutic drug monitoring in oncology:IATDMCT recommendations for 5-fluorouracil therapy
10.1002/cpt.1124 · 2019 · External reference
Research progress on resistance mechanisms and new therapeutic strategies of 5-fluorouracil in the treatment of colon cancer
2025 · External reference
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
10.1200/jco.1999.17.4.1105 · 1999 · External reference
Clinical significance of detecting 5-FU plasma concentration in colorectal cancer patients by high-performance liquid chromatography
2010 · External reference
LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients
10.1002/bmc.2741 · 2013 · External reference
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
10.1515/cclm-2012-0641 · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma
10.1016/j.jpba.2016.04.039 · 2016 · External reference
Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma
10.1515/cclm-2021-0921 · 2022 · External reference
Phenotyping of Uracil and 5-Fluorouracil Metabolism Using LC-MS/MS for Prevention of Toxicity and Dose Adjustment of Fluoropyrimidines
10.1097/ftd.0000000000000768 · 2020 · External reference
Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio
10.2217/pgs.14.126 · 2014 · External reference
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer
10.1200/jco.2007.13.3934 · 2008 · External reference
Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6
10.1634/theoncologist.2011-0357 · 2012 · External reference
A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy
10.1634/theoncologist.2014-0132 · 2014 · External reference
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
10.1002/cpt.911 · 2018 · External reference
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
10.1200/jco.2015.63.1325 · 2016 · External reference
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
10.1016/s1470-2045(18)30686-7 · 2018 · External reference
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
10.1038/bjc.2017.94 · 2017 · External reference
